- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04993365
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
October 7, 2023 updated by: Sinovac Research and Development Co., Ltd.
A Randomized and Controlled Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old
This study is a randomized and controlled phase Ⅳ clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research & Development Co., Ltd.
The purpose of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell), Inactivated co-administration with EV71 vaccine
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized and controlled phase Ⅳ clinical trial in children aged 3-5 years old.
The purpose of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell), Inactivated co-administration with EV71 vaccine.The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.A total of 520 subjects aged 3-5 years old will be enrolled.Subjects will be randomly divided into 2 groups in a ratio of 1:1.The experimental group is the combined immunization group, which will receive the first dose of COVID-19 vaccine and the second dose of COVID-19 vaccine and EV71 vaccine on day 28;Control group is the Non-combined immunization group , which will receive the first dose of COVID-19 vaccine on day 0 ,the first dose of EV71 vaccine on day 14 ,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
Study Type
Interventional
Enrollment (Actual)
520
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Yangchun, Guangdong, China, 529699
- Yangchun Center for Disease Control and Prevention
-
Zhanjiang, Guangdong, China, 524005
- Zhanjiang Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 3 years (Child)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Children aged 3-5 years ;
- The subject and/or guardian can understand and voluntarily sign the informed consent form
- Proven legal identity;
Exclusion Criteria:
- History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within 14 days;
- History of multiple system inflammatory syndrome (MIS-C);
- History of hand, foot and mouth disease, herpetic angina or EV71 vaccination;
- History of asthma, history of allergy to the vaccine or vaccine components,or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
- Congenital malformations or developmental disorders, genetic defects,severe malnutrition, etc.;
- Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency / immunosuppression(HIV,history after organ transplantation);
- Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy,abnormal platelets) or obvious bruising or blood coagulation;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- History of drug abuse;
- Receipt of blood products within in the past 3 months;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 14 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Axillary temperature >37.0°C;
- The subjects participated in other clinical trials during the follow-up period, or will be planned within 3 months;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
The experimental group is also called the combined immunization group .260
participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
|
The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.
The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Other Names:
|
Active Comparator: Control Group
The control group is also called the Non-combined immunization group.260
participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
|
The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.
The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity index-Seroconversion rate of the neutralizing antibody to live SARS-CoV-2
Time Frame: Day 28 after the second dose of COVID-19 vaccine
|
Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose of COVID-19 vaccine
|
Day 28 after the second dose of COVID-19 vaccine
|
Immunogenicity index-Seroconversion rate of the neutralizing antibody to EV71
Time Frame: Day 28 after the second dose of EV71 vaccine
|
Seroconversion rate of the neutralizing antibody to EV71 at day 28 after the second dose of EV71 vaccine
|
Day 28 after the second dose of EV71 vaccine
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity index-Seropositivity rate of the neutralizing antibody to live SARS-CoV-2
Time Frame: Day 28 after the second dose of COVID-19 vaccine
|
Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose of COVID-19 vaccine.
|
Day 28 after the second dose of COVID-19 vaccine
|
Immunogenicity index- GMT of the neutralizing antibody to live SARS-CoV-2
Time Frame: Day 28 after the second dose of COVID-19 vaccine
|
GMT of the neutralizing antibody to live SARS-CoV-2 at day 28 after after the second dose of COVID-19 vaccine.
|
Day 28 after the second dose of COVID-19 vaccine
|
Immunogenicity index-GMI of the neutralizing antibody to live SARS-CoV-2
Time Frame: Day 28 after the second dose of COVID-19 vaccine
|
GMI of the neutralizing antibody to live SARS-CoV-2 at day 28 after after the second dose of COVID-19 vaccine.
|
Day 28 after the second dose of COVID-19 vaccine
|
Immunogenicity index-Seropositive rate of the neutralizing antibody to EV71
Time Frame: Day 28 after the second dose of EV71
|
Seropositive rate of the neutralizing antibody to EV71 at day 28 after the second dose of EV71
|
Day 28 after the second dose of EV71
|
Immunogenicity index-GMT of the neutralizing antibody to EV71
Time Frame: Day 28 after the second dose of EV71
|
GMT of the neutralizing antibody to EV71 at day 28 after the second dose of EV71
|
Day 28 after the second dose of EV71
|
Immunogenicity index-GMI of the neutralizing antibody to EV71
Time Frame: Day 28 after the second dose of EV71
|
GMI of the neutralizing antibody to EV71 at day 28 after the second dose of EV71
|
Day 28 after the second dose of EV71
|
Safety index-Incidence of the adverse reactions
Time Frame: From day 0 to day 7 after each dose
|
Incidence of the adverse reactions from day 0 to day 7 after each dose
|
From day 0 to day 7 after each dose
|
Safety index-Incidence of the adverse reactions
Time Frame: From day 0 to 28 days after the last dose
|
Incidence of the adverse reactions from day 0 to 28 days after the last dose
|
From day 0 to 28 days after the last dose
|
Safety index-Incidence of the serious adverse events and the adverse events of special interest
Time Frame: From the beginning vaccination to 6 months after the last dose
|
Incidence of the serious adverse events and the adverse events of special interest from the beginning vaccination to 6 months after the last dose
|
From the beginning vaccination to 6 months after the last dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity index-Seropositive rate of the neutralizing antibody to live SARS-CoV-2
Time Frame: 6 months after the second dose of COVID-19 vaccine
|
Seropositive rate and GMT of the neutralizing antibody to live SARS-CoV-2 6 months after the second dose of COVID-19 vaccine
|
6 months after the second dose of COVID-19 vaccine
|
Immunogenicity index- GMT of the neutralizing antibody to live SARS-CoV-2
Time Frame: 6 months after the second dose of COVID-19 vaccine
|
GMT of the neutralizing antibody to live SARS-CoV-2 6 months after the second dose of COVID-19 vaccine
|
6 months after the second dose of COVID-19 vaccine
|
Immunogenicity index-Seropositive rate of the neutralizing antibody to EV71
Time Frame: 6 months after the second dose of EV71 vaccine
|
Seropositive rate of the neutralizing antibody to EV71 6 months after the second dose of EV71 vaccine
|
6 months after the second dose of EV71 vaccine
|
Immunogenicity index-GMT of the neutralizing antibody to EV71
Time Frame: 6 months after the second dose of EV71 vaccine
|
GMT of the neutralizing antibody to EV71 6 months after the second dose of EV71 vaccine.
|
6 months after the second dose of EV71 vaccine
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Zhuhang Huang, Master, Guangdong Center for Disease Prevention and Control
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 5, 2021
Primary Completion (Actual)
July 14, 2022
Study Completion (Actual)
July 14, 2022
Study Registration Dates
First Submitted
August 2, 2021
First Submitted That Met QC Criteria
August 4, 2021
First Posted (Actual)
August 6, 2021
Study Record Updates
Last Update Posted (Estimated)
October 10, 2023
Last Update Submitted That Met QC Criteria
October 7, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-nCOV-4002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Experimental Group
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedChronic Low Back Pain | Fear of Pain | Fear of InjuryUnited States
-
Riphah International UniversityCompletedSports Physical TherapyPakistan
-
Ataturk UniversityArtvin Coruh UniversityCompleted
-
Istanbul University - Cerrahpasa (IUC)Completed
-
Riphah International UniversityRecruitingEffects of Strength Training on Freestyle Swimming Performance and Core Muscles Strength in SwimmersSports Physical TherapyPakistan
-
Cristian AlvarezUniversidad de La FronteraCompleted
-
RezoluteActive, not recruitingDiabetic Macular EdemaUnited States
-
Dr. Sobia HasanRecruiting
-
Ataturk UniversityNot yet recruitingQuality of Life | Fatigue | Gestational Diabetes Mellitus in Pregnancy | Pregnancy in Diabetic